Back to results
US 2019/0338029 A1Published application
Cell engaging binding molecules
AssigneeY-Biologics Inc.
InventorsSeil JANG, Bum-Chan PARK, Young Woo PARK
Life of this patent
Estimating the term…
Abstract
The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
Claims30
A binding molecule, comprising:
- (a) a first polypeptide and a second polypeptide, each comprising an antibody light chain,
- (b) a third polypeptide comprising, in the order from N-terminus to C-terminus, a first variable heavy (VH) region and a first constant heavy 1 (CH1) region, and a second VH region;
- and
- (c) a fourth polypeptide comprising, in the order from N-terminus to C-terminus, a third VH region and a second CH1 region, and a variable light (VL) region,
- wherein the first polypeptide and the first VH region and the first CH1 region of the third polypeptide form a first antigen binding Fab region;
- wherein the second polypeptide and the third VH region and the second CH1 region of the fourth polypeptide form a second antigen binding Fab region;
- wherein the second VH region of the third polypeptide and the VL region of the fourth polypeptide form an antigen binding Fv region;
- and
- wherein the first Fab region and the second Fab region binds to Programmed Death-Ligand 1 (PD-L1), and the Fv region binds to Cluster of Differentiation 3 (CD3).
6 more elements
A method of making a binding molecule, comprising:
- (i) expressing the binding molecule from one or more vectors in a host cell, wherein the one or more vectors comprise
- (a) a first nucleic acid encoding a first polypeptide and a second nucleic acid encoding a second polypeptide, wherein each polypeptide comprises an antibody light chain,
- (b) a third nucleic acid encoding a third polypeptide comprising, in the order from N-terminus to C-terminus, a first variable heavy (VH) region and a first constant heavy 1 (CH1) region, and a second VH region;
- and
- (c) a fourth nucleic acid encoding a fourth polypeptide comprising, in the order from N-terminus to C-terminus, a third VH region and a second CH1 region, and a variable light (VL) region,
- wherein the first polypeptide and the first VH region and the first CH1 region of the third polypeptide form a first antigen binding Fab region;
- wherein the second polypeptide and the third VH region and the second CH1 region of the fourth polypeptide form a second antigen binding Fab region;
- wherein the second VH region of the third polypeptide and the VL region of the fourth polypeptide form an antigen binding Fv region;
- and
- wherein the first Fab region and the second Fab region bind to PD-L1, and the Fv region binds to CD3, and
- (ii) purifying the binding molecule.
8 more elements
A pharmaceutical composition comprising a binding molecule and a pharmaceutically acceptable carrier, wherein the binding molecule comprises:
- (a) a first polypeptide and a second polypeptide, each comprising an antibody light chain,
- (b) a third polypeptide comprising, in the order from N-terminus to C-terminus, a first variable heavy (VH) region and a first constant heavy 1 (CH1) region, and a second VH region;
- and
- (c) a fourth polypeptide comprising, in the order from N-terminus to C-terminus, a third VH region and a second CH1 region, and a variable light (VL) region,
- wherein the first polypeptide and the first VH region and the first CH1 region of the third polypeptide form a first antigen binding Fab region;
- wherein the second polypeptide and the third VH region and the second CH1 region of the fourth polypeptide form a second antigen binding Fab region;
- wherein the second VH region of the third polypeptide and the VL region of the fourth polypeptide form an antigen binding Fv region;
- and
- wherein the first Fab region and the second Fab region binds to PD-L1, and the Fv region binds to CD3.
6 more elements
A method of treating a disease or condition in a subject comprising administering a therapeutically effective amount of a binding molecule to the subject, wherein the binding molecule comprises:
- (a) a first polypeptide and a second polypeptide, each comprising an antibody light chain,
- (b) a third polypeptide comprising, in the order from N-terminus to C-terminus, a first variable heavy (VH) region and a first constant heavy 1 (CH1) region, and a second VH region;
- and
- (c) a fourth polypeptide comprising, in the order from N-terminus to C-terminus, a third VH region and a second CH1 region, and a variable light (VL) region,
- wherein the first polypeptide and the first VH region and the first CH1 region of the third polypeptide form a first antigen binding Fab region;
- wherein the second polypeptide and the third VH region and the second CH1 region of the fourth polypeptide form a second antigen binding Fab region;
- wherein the second VH region of the third polypeptide and the VL region of the fourth polypeptide form an antigen binding Fv region;
- and
- wherein the first Fab region and the second Fab region binds to PD-L1, and the Fv region binds to CD3.
6 more elements
Dependencies are inferred from the claim text.